糖尿病前期市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類別、年齡層、地區和競爭格局分類，2021-2031年

全球糖尿病前期市場預計將從 2025 年的 3.5171 億美元大幅成長至 2031 年的 6.6463 億美元，複合年成長率高達 11.19%。

該市場涵蓋多種解決方案，包括診斷技術、藥物療法和數位健康工具，所有這些方案都旨在識別和管理中間型高血糖，防止其發展為第2型糖尿病。推動這一市場成長的關鍵因素是全球肥胖率上升和久坐生活方式的日益普遍，凸顯了早期預防性醫療保健對於減輕慢性疾病帶來的長期經濟負擔的重要性。此外，政府支持的篩檢計畫和推廣預防醫學的公共衛生宣傳活動的日益普及，也顯著提升了對能夠早期發現和有效管理糖尿病前期解決方案的需求。儘管市場成長迅速，但其擴張的主要障礙仍然是診斷率低和大眾對糖尿病前期嚴重性的認知不足。由於糖尿病前期通常無症狀，大量患者未被診斷，導致藥物療​​法和監測產品的潛在患者群體有限。根據國際糖尿病聯盟（IDF）2024年的數據，全球約有6.35億成年人葡萄糖耐受不良。這表明，這種疾病的高發生率與積極尋求或接受醫療保健的人數相對較少之間存在顯著差異。

市場促進因素

全球肥胖和久坐的生活方式是全球糖尿病前期市場的主要促進因素。由於體重增加會對胰島素敏感性產生負面影響，高體重指數（BMI）族群的不斷成長擴大了預防性健康干預措施的潛在用戶層。這一人口趨勢促使醫療保健系統更加重視體重管理，以預防代謝併發症。根據世界肥胖聯盟發布的《2024年世界肥胖地圖集》（2024年3月），預計2035年，全球肥胖成年人數將達到15.3億。這一顯著成長推動了旨在改善代謝風險因素、防止其惡化的生活方式改善項目和診斷工具的開發。此外，創新藥物療法的引入正在極大地改變體重管理的治療方法。新型Glucagon-Like Peptide-1受體促效劑為延緩疾病進展提供了強大的工具，並且已有臨床證據顯示其能夠預防第2型糖尿病的發生。例如，禮來公司（Eli Lilly and Company）的SURMOUNT-1試驗結果（2024年8月公佈）顯示，每週一次注射替Tirzepatide可顯著降低糖尿病前期和肥胖成年人患有2型糖尿病的風險達94%，這印證了藥物治療在預防醫學中的價值。從區域角度來看，市場規模也顯而易見。根據美國疾病管制與預防中心（CDC）統計，到2024年，美國約有9,760萬成年人處於糖尿病前期狀態，這意味著有大量人口可以從這些治療方法中獲益。

市場挑戰

全球糖尿病前期市場擴張的一大障礙是診斷率嚴重不足，這主要是因為疾病通常無症狀。與許多立即出現症狀或症狀嚴重的慢性疾病不同，糖尿病前期通常在不知不覺中發展，這意味著數百萬人對自身健康狀況毫不知情。這種缺乏明顯症狀的情況導致糖尿病前期的高盛行率與實際臨床干預需求之間存在巨大差距。由於患者沒有任何症狀，他們不太可能主動尋求篩檢或使用藥物和數位健康解決方案，而這些正是該市場的主要收入來源。因此，實際尋求治療的患者人數遠低於受影響的總數，這直接限制了預防性療法和監測技術的商業性可行性。近期統計數據清晰地顯示了這一巨大的診斷差距。美國疾病管制與預防中心 (CDC) 在 2024 年報告稱，約 9,800 萬美國成年人患有糖尿病前期，其中超過 80% 的人對此毫不知情。這一數字凸顯了一個巨大的障礙。這是因為，如果沒有正式診斷，這些人就無法參與疾病管理計畫或接受預防性治療。因此，診斷試劑和治療藥物的生產商面臨瓶頸：儘管理論上市場潛力巨大，但大多數潛在用戶仍被排除在傳統醫療體系之外，嚴重限制了其實際市場覆蓋範圍。

市場趨勢

全球糖尿病前期市場正日益轉向積極的代謝管理，將持續血糖監測（CGM）應用於尚未確診糖尿病的人。製造商正在推出非處方生物感測器，使用戶無需處方箋即可監測血糖值波動並調整生活方式。這項策略有效地吸引了糖尿病前期人群，並透過提供飲食和運動如何影響血糖值的即時回饋，繞過了傳統的臨床障礙。這一趨勢的商業性成功顯而易見。 2025年1月（「JPM25：Dexcom預測2025年成長」），Fierce Biotech報告指出，Dexcom的非處方穿戴裝置「Stelo」在上市後不久便獲得了超過14萬用戶，並創造了2,200萬美元的收入，凸顯了市場對預防性監測解決方案的強勁需求。同時，人工智慧（AI）在早期風險評估中的應用正在解決以人性化的預防項目在規模化方面面臨的挑戰。人工智慧平台能夠分析使用者數據，提供個人化指導，從而以經濟高效的方式管理大規模未確診的糖尿病前期人口。這些先進工具提供持續的行為支持，其效果與傳統的面對面方法相當。約翰霍普金斯大學醫學院於2025年10月證實了這項有效性。根據他們的報告《人工智慧驅動的糖尿病預防計畫與人工主導的計畫效果相當》，使用人工智慧應用程式的參與者中有31.7%達到了官方設定的糖尿病風險降低目標，這一結果與主導干預所取得的成果一致。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球糖尿病前期市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物分類（雙胍類、胰島素增敏劑、Glucagon-Like Peptide-1促效劑（GLP-1）、SGLT2抑制劑、DPP-4抑制劑、其他）
  • 依年齡層別分類（兒童（12-18歲）、成人（18-49歲）、老年人（50歲以上））
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美糖尿病前期市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲糖尿病前期市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區糖尿病前期市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲糖尿病前期市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲糖尿病前期市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球糖尿病前期市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novo Nordisk A/S
• Valbiotis
• RESVERLOGIX
• Caelus Health
• Scimar
• Boston Pharmaceuticals
• APHAIA PHARMA AG
• AstraZeneca Plc
• Bristol-Myers Squibb Company
• Pfizer Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Prediabetes Market is projected to expand significantly, increasing from USD 351.71 million in 2025 to USD 664.63 million by 2031, demonstrating an impressive compound annual growth rate (CAGR) of 11.19%. This market encompasses various solutions, including diagnostic technologies, pharmaceutical treatments, and digital health tools, all aimed at identifying and managing intermediate hyperglycemia before it advances to type 2 diabetes. Key factors propelling this growth are the rising global rates of obesity and sedentary lifestyles, which highlight the critical need for early preventive healthcare to reduce the long-term financial strain associated with chronic illnesses. Additionally, the increasing implementation of government-supported screening programs and public health campaigns that advocate for preventive care is significantly boosting the demand for solutions that enable early detection and effective management of prediabetes.Despite this growth, a primary obstacle to market expansion is the low diagnostic rate and insufficient public understanding of prediabetes's seriousness. A substantial number of individuals remain undiagnosed because prediabetes often presents without symptoms, thereby limiting the potential patient base for pharmacological and monitoring products. Data from the International Diabetes Federation in 2024 indicates that approximately 635 million adults globally were living with impaired glucose tolerance, illustrating a considerable disparity between the condition's high prevalence and the relatively small number of individuals who are actively seeking or receiving clinical attention.

Market Driver

The increasing global incidence of obesity and sedentary lifestyles serves as a key driving force for the Global Prediabetes Market. Since higher body weight negatively affects insulin sensitivity, the growing population with elevated body mass index expands the potential user base for preventive health interventions. This demographic trend is prompting healthcare systems to focus more on weight management to prevent metabolic complications. The World Obesity Federation's 'World Obesity Atlas 2024' (March 2024) projects that by 2035, the number of adults living with obesity will reach 1.53 billion, a substantial increase that stimulates the creation of lifestyle modification programs and diagnostic tools designed to reverse metabolic risk factors before they worsen.Moreover, the introduction of innovative pharmacological treatments for weight management is transforming the therapeutic landscape. Newer glucagon-like peptide-1 receptor agonists offer powerful ways to slow down disease progression, with clinical evidence demonstrating their capacity to prevent the transition to type 2 diabetes. For instance, the 'SURMOUNT-1 study results' from Eli Lilly and Company (August 2024) revealed that weekly tirzepatide injections significantly cut the risk of developing type 2 diabetes by 94% in adults with prediabetes and obesity, thus confirming the value of pharmacotherapy in preventive care. Regionally, the market's significant size is apparent; in 2024, about 97.6 million adults in the United States had prediabetes, according to the Centers for Disease Control and Prevention, indicating a large population that could benefit from these treatments.

Market Challenge

A significant impediment to the expansion of the Global Prediabetes Market is the extensive under-diagnosis, largely due to the condition's predominantly asymptomatic nature. Unlike many chronic illnesses that manifest with immediate or severe symptoms, prediabetes typically progresses unnoticed, leaving millions unaware of their health status. This lack of visible symptoms creates a substantial divergence between the high prevalence of prediabetes and the actual demand for clinical interventions. Since individuals do not experience illness, they are less inclined to actively pursue screening or adopt the pharmaceutical and digital health solutions that constitute the market's primary revenue sources. As a result, the population of patients who are actually seeking treatment is considerably smaller than the total number of affected individuals, which directly constrains the commercial viability of preventive therapies and monitoring technologies.This considerable gap in diagnosis is vividly demonstrated by recent statistics: the Centers for Disease Control and Prevention reported in 2024 that over 80 percent of the nearly 98 million American adults with prediabetes were unaware of their condition. This figure underscores a crucial barrier, as these individuals cannot be enrolled in disease management programs or prescribed preventive treatments without a formal diagnosis. Consequently, manufacturers of diagnostic tests and therapeutic agents encounter a bottleneck where, despite immense theoretical market potential, practical market reach is severely limited because most potential users remain outside the conventional healthcare system.

Market Trends

The Global Prediabetes Market is increasingly leaning towards proactive metabolic management through the incorporation of Continuous Glucose Monitoring (CGM) for individuals without diagnosed diabetes. Manufacturers are introducing over-the-counter biosensors that empower users to observe their glycemic fluctuations and adjust their lifestyle choices without requiring a prescription. This strategy effectively engages the prediabetic population by offering instant feedback on how food and physical activity influence blood sugar levels, thereby circumventing conventional clinical obstacles. The commercial success of this trend is evident: Fierce Biotech reported in January 2025 (in 'JPM25: Dexcom predicts 2025 growth') that Dexcom's Stelo over-the-counter wearable quickly amassed over 140,000 users and generated $22 million in revenue post-launch, confirming a strong demand for preventive monitoring solutions.Concurrently, the utilization of artificial intelligence (AI) for early risk assessment is addressing the scalability challenges associated with human-focused prevention programs. AI-powered platforms are now capable of analyzing user data to provide tailored coaching, facilitating the cost-effective management of the large, undiagnosed prediabetic demographic. These advanced tools deliver continuous behavioral support with effectiveness comparable to traditional in-person methods. This efficacy was corroborated by Johns Hopkins Medicine in October 2025, where their 'AI-Powered Diabetes Prevention Program Shows Similar Benefits to Those Led by People' report indicated that 31.7% of participants using an AI-driven application achieved official diabetes risk reduction goals, results that mirrored those obtained through human-led interventions.

Key Market Players

• Novo Nordisk A/S
• Valbiotis
• RESVERLOGIX
• Caelus Health
• Scimar
• Boston Pharmaceuticals
• APHAIA PHARMA AG
• AstraZeneca Plc
• Bristol-Myers Squibb Company
• Pfizer Inc

Report Scope

In this report, the Global Prediabetes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prediabetes Market, By Drug Class

• Biguanide
• Thiazolidinediones
• Glucagon-like peptide-1 agonists (GLP-1)
• SGLT2 inhibitors
• DPP-4 inhibitors
• Others

Prediabetes Market, By Age Group

• Children (12-18 years)
• Adults (18-49)
• Elderly (50+)

Prediabetes Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prediabetes Market.

Available Customizations:

Global Prediabetes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prediabetes Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Biguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, Others)
  • 5.2.2. By Age Group (Children (12-18 years), Adults (18-49), Elderly (50+))
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Prediabetes Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Age Group
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prediabetes Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Age Group
  • 6.3.2. Canada Prediabetes Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Age Group
  • 6.3.3. Mexico Prediabetes Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Age Group

7. Europe Prediabetes Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Age Group
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Prediabetes Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Age Group
  • 7.3.2. France Prediabetes Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Age Group
  • 7.3.3. United Kingdom Prediabetes Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Age Group
  • 7.3.4. Italy Prediabetes Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Age Group
  • 7.3.5. Spain Prediabetes Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Age Group

8. Asia Pacific Prediabetes Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Age Group
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Prediabetes Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Age Group
  • 8.3.2. India Prediabetes Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Age Group
  • 8.3.3. Japan Prediabetes Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Age Group
  • 8.3.4. South Korea Prediabetes Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Age Group
  • 8.3.5. Australia Prediabetes Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Age Group

9. Middle East & Africa Prediabetes Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Age Group
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Prediabetes Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Age Group
  • 9.3.2. UAE Prediabetes Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Age Group
  • 9.3.3. South Africa Prediabetes Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Age Group

10. South America Prediabetes Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Age Group
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Prediabetes Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Age Group
  • 10.3.2. Colombia Prediabetes Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Age Group
  • 10.3.3. Argentina Prediabetes Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Age Group

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Prediabetes Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novo Nordisk A/S
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Valbiotis
• 15.3. RESVERLOGIX
• 15.4. Caelus Health
• 15.5. Scimar
• 15.6. Boston Pharmaceuticals
• 15.7. APHAIA PHARMA AG
• 15.8. AstraZeneca Plc
• 15.9. Bristol-Myers Squibb Company
• 15.10. Pfizer Inc

16. Strategic Recommendations

17. About Us & Disclaimer